Heather Denroche
Director, Preclinical Development Integrated Nanotherapeutics
Dr. Heather Denroche has 15 years of experience in preclinical diabetes research. She obtained her BSc in Biochemistry and PhD in Cell and Developmental Biology from the University of British Columbia and trained as a postdoctoral fellow at BC Children’s Hospital Research Institute. Dr. Denroche has won numerous awards from federal and international agencies including CIHR and JDRF. Her background in diabetes and immunology is instrumental to our company’s focus on developing treatments for autoimmune and inflammatory diseases. She directs R&D efforts in candidate drug selection and preclinical development
Seminars
Wednesday 4th March 2026
Advancing mRNA-LNP Autoantigen Therapies: Engineering Peripheral Tolerance & Driving Toward First-in-Human Studies
1:30 pm
- Explore how mRNA-encoded beta-cell autoantigens with immune modulators drive peripheral tolerance
- Delve into lipid nanoparticle delivery facilitating tolerogenic antigen presentation and Treg-aligned immunoreprogramming
- Discover the translational trajectory toward first-in-human studies in 2027, encompassing CMC scale-up, toxicology studies, and early regulatory engagement to validate safety, manufacturability, and indication expansion
